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Randomisation in clinical trials continues to be contro-
versial and to be attacked on ethical, practical and philo-
sophical grounds. Whatever the practical, moral or
philosophical limitations of randomisation may be,
many of the attacks reveal that the critics do not under-
stand why randomisation is carried out and what its
purpose is. In some cases one may even claim that the
defenders of randomisation are equally confused.
S e v e nc o m m o nm y t h sa r ee x a m i n e di nt h i sp a p e r ,
namely, that 1. patients are treated simultaneously in
clinical trials 2. balance of prognostic factors in neces-
sary for valid inference 3. observed covariates may be
ignored because one has randomized 4. blinding can be
carried out effectively without randomisation 5. rando-
misation is inefficient 6. randomisation precludes balan-
cing covariates and 7. large trials are more balanced
than small ones.
Many of these myths are related to the problem of
distinguishing between conditional and unconditional
inference and the relevance of this distinction is
explained with a simple game of chance involving two
fair dice, and played in three variants, and a statistician
who has to correctly call the odds of obtaining a total
score of ten. Others simply arise, because many who
have written on clinical trials have not designed them.
In fact, what some critics have overlooked is that
when it comes to allocating treatments to patients, ‘the
devil is in the detail’. A useful discipline that can be
recommended to any would-be critic of randomisation
in clinical trials is to attempt to write a detailed proto-
col, capable of being followed by another. This ‘thought
experiment’ is useful in revealing potential problems
with any scheme.
Finally a technical problem to do with the estimation
of nuisance parameters in analysis of covariance is
covered.
It is concluded that the debate on the role of rando-
mised clinical trials in evidence based medicine would
be improved if those debating it paid careful attention
to what randomisation can and cannot do to strengthen
the validity of inferences regarding the effects of
treatment.
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